SAN DIEGO, Oct. 05, 2023 (GLOBE NEWSWIRE) -- Biora Therapeutics, Inc. (Nasdaq: BIOR), the biotech company that is reimagining therapeutic delivery, presented data on oral delivery of a GLP-1 receptor agonist with its BioJet systemic oral delivery platform in a short oral discussion titled “Evaluation of the Pharmacokinetics of Glucagon-Like-Peptide-1 Receptor Agonist Delivered through the BioJet™ Biotherapeutic Delivery Platform in Swine” at the 59th annual meeting of the European Association for the Study of Diabetes, in Hamburg, Germany.

“In recent studies, we assessed the bioavailability of semaglutide when delivered via our autonomous next-generation BioJet device in a porcine model. Across three studies, 96% of animals (22/23) showed semaglutide in systemic circulation at clinically relevant levels for up to ten days following administration,” said Sharat Singh, PhD, Head of Research at Biora Therapeutics. “Among the 22 animals dosed with semaglutide, oral bioavailability averaged 20.5% ± 15.3%, compared to IV control, which exceeds both the device performance and bioavailability targets set by us and our collaborators,” continued Dr. Singh.

“The category-leading bioavailability results for our autonomous, next-gen BioJet device, along with its ability to deliver existing liquid formulations at multi-milligram doses similar to injection, have enabled us to accelerate testing with our collaborators’ molecules,” said Adi Mohanty, Chief Executive Officer of Biora Therapeutics. “We are seeing increased interest in our platform and continue to advance our stated goal to progress our collaborations and rapidly work towards meaningful partnerships,” continued Mr. Mohanty.

The studies included single, approximately 1 mg doses of semaglutide in a liquid formulation delivered via the BioJet device. Devices were administered endoscopically, as is typical in a porcine model, and then released for autonomous activation. Blood sampling was performed from zero to 240 hours post-dose, with comparison to a control animal with drug administered intravenously. The presentation can be viewed on the European Association for the Study of Diabetes website and is also available on the Biora Therapeutics website.

About the BioJet™ Systemic Oral Delivery Platform 

Biora's BioJet systemic oral therapeutics platform uses an ingestible capsule for needle-free, oral delivery of large molecules designed to achieve systemic bioavailability and replace injection for better management of chronic diseases.  

The BioJet platform uses an ingestible device designed to transit through the digestive system and activate in the small intestine, where liquid jets deliver drug directly into the small intestine for uptake into systemic circulation. The BioJet device is approximately the size of a multivitamin and is designed to autonomously deliver a wide range of large molecules, such as proteins, peptides, and nucleic acids, in liquid formulation at multi-milligram doses, without requiring complex reformulation. 

Biora holds a comprehensive patent position for the BioJet systemic oral delivery platform, with approximately 11 issued patents and 27 pending applications that cover its delivery platform and methods for using the platform to treat a disease or condition in a patient using liquid jet delivery of a wide range of drugs.  

About Biora Therapeutics

Biora Therapeutics is the biotech company that is reimagining therapeutic delivery. By creating innovative smart pills designed for targeted drug delivery to the GI tract, and systemic, needle-free delivery of biotherapeutics, the company is developing therapies to improve patients’ lives.

Biora is focused on development of two therapeutics platforms: the NaviCap™ targeted oral delivery platform, which is designed to improve outcomes for patients with inflammatory bowel disease through treatment at the site of disease in the gastrointestinal tract, and the BioJet™ systemic oral delivery platform, which is designed to replace injection for better management of chronic diseases through needle-free, oral delivery of large molecules.

For more information, visit bioratherapeutics.com or follow the company on LinkedIn or Twitter.

Safe Harbor Statement or Forward-Looking Statements

This press release contains “forward-looking statements” within the meaning of the “safe harbor” provisions of the Private Securities Litigation Reform Act of 1995, which statements are subject to substantial risks and uncertainties and are based on estimates and assumptions. All statements, other than statements of historical facts included in this press release, including statements concerning the progress and future expectations and goals of our research and development and clinical efforts, are forward-looking statements. In some cases, you can identify forward-looking statements by terms such as “may,” “might,” “will,” “objective,” “intend,” “should,” “could,” “can,” “would,” “expect,” “believe,” “design,” “estimate,” “predict,” “potential,” “plan,” “target,” or the negative of these terms, and similar expressions intended to identify forward-looking statements. These statements reflect our plans, estimates, and expectations, as of the date of this press release. These statements involve known and unknown risks, uncertainties and other factors that could cause our actual results to differ materially from the forward-looking statements expressed or implied in this press release. Such risks, uncertainties, and other factors include, among others, our ability to innovate in the field of therapeutics, our ability to make future filings and initiate clinical trials on expected timelines or at all, our ability to obtain and maintain regulatory approval or clearance of our products on expected timelines or at all, our plans to research, develop, and commercialize new products, the unpredictable relationship between preclinical study results and clinical study results, our expectations regarding allowed patents or intended grants to result in issued or granted patents, our expectations regarding opportunities with current or future pharmaceutical collaborators, our ability to raise sufficient capital to achieve our business objectives, and those risks described in “Risk Factors” and “Management’s Discussion and Analysis of Financial Condition and Results of Operations” in our Annual Report on Form 10-K for the year ended December 31, 2022 filed with the SEC and other subsequent documents, including Quarterly Reports, that we file with the SEC.

Biora Therapeutics expressly disclaims any obligation to update any forward-looking statements whether as a result of new information, future events or otherwise, except as required by law. 

Investor Contact
Chuck Padala
Managing Director, LifeSci Advisors
This email address is being protected from spambots. You need JavaScript enabled to view it.
(646) 627-8390

Media Contact
This email address is being protected from spambots. You need JavaScript enabled to view it.